Drug intelligence / Profile preview

flotegatide (18F) + RGD (68Ga)

Development stage: Discontinued
Lead developer: Siemens Healthineers
Modality: Peptide-Drug Conjugates → Peptide Conjugates → Peptides
Administration: Intravenous

Overview

A combination of two radiolabeled RGD peptides used for PET imaging of integrin αvβ3 expression. Flotegatide (18F) was developed by GE Healthcare with a core peptide sequence of ACDRGDCFCG, optimized through cyclization and introduction of two disulfide bonds. It shows highest binding affinity for integrin αvβ5 (IC50 0.1 nM), followed by integrin αvβ3 (IC50 11.1 nM). The 68Ga-labeled RGD peptides have similar dosimetry profiles but shorter physical half-life compared to 18F-labeled counterparts.

Other names: RGD F18Flotegatide F18RGD-F18RGD-F-18RGD-F 18

Targets

αVβ3 (Integrin αVβ3)αVβ5 (Integrin αVβ5)

Beyond the preview

Go deeper on flotegatide (18F) + RGD (68Ga).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on flotegatide (18F) + RGD (68Ga).

Explore the full profile